• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Believe it or not: how much can we rely on published data on potential drug targets?

作者信息

Prinz Florian, Schlange Thomas, Asadullah Khusru

出版信息

Nat Rev Drug Discov. 2011 Aug 31;10(9):712. doi: 10.1038/nrd3439-c1.

DOI:10.1038/nrd3439-c1
PMID:21892149
Abstract
摘要

相似文献

1
Believe it or not: how much can we rely on published data on potential drug targets?信不信由你：我们能在多大程度上依赖已发表的关于潜在药物靶点的数据？
Nat Rev Drug Discov. 2011 Aug 31;10(9):712. doi: 10.1038/nrd3439-c1.
2
Trial watch: Phase II failures: 2008-2010.试验观察：II期试验失败情况：2008 - 2010年
Nat Rev Drug Discov. 2011 May;10(5):328-9. doi: 10.1038/nrd3439.
3
Planning and analysis of repeated measures at key time-points in clinical trials sponsored by pharmaceutical companies.
Stat Med. 1999 Apr 30;18(8):961-73. doi: 10.1002/(sici)1097-0258(19990430)18:8<961::aid-sim83>3.0.co;2-i.
4
The clinical development of molecularly targeted agents in combination with radiation therapy: a pharmaceutical perspective.分子靶向药物联合放射治疗的临床发展：药物学视角。
Int J Radiat Oncol Biol Phys. 2012 Nov 15;84(4):e447-54. doi: 10.1016/j.ijrobp.2012.05.019. Epub 2012 Jul 20.
5
[Attractiveness of France for international clinical trials in 2012: 6(th) survey assessed by Leem (French association of pharmaceutical companies)].2012年法国对国际临床试验的吸引力：由法国制药公司协会（Leem）评估的第六次调查
Therapie. 2013 Jan-Feb;68(1):1-18. doi: 10.2515/therapie/2013011. Epub 2013 Mar 14.
6
[Application of pharmacogenomics and other new technologies to drug development].
Med Clin (Barc). 2013 Jun 18;140(12):558-63. doi: 10.1016/j.medcli.2013.02.010. Epub 2013 Apr 10.
7
"Profoundly Saddened" Lysogene Discloses Child's Death in Phase II/III Trial.“深感悲痛”，Lysogene披露其二期/三期试验中儿童死亡事件。
Hum Gene Ther. 2020 Nov;31(21-22):1141-1143. doi: 10.1089/hum.2020.29139.bfs.
8
Current perspectives on the design of phase II trials of new drugs for the treatment of heart failure.
Am Heart J. 2000 Apr;139(4):S202-6. doi: 10.1016/s0002-8703(00)90074-7.
9
Market watch: Upcoming market catalysts in Q2 2013.市场观察：2013年第二季度即将出现的市场催化剂。
Nat Rev Drug Discov. 2013 Apr;12(4):254. doi: 10.1038/nrd3990.
10
A decision analytic approach to a futility analysis of a phase II pharmaceutical study.一种用于II期药物研究无效性分析的决策分析方法。
J Biopharm Stat. 2001 Nov;11(4):209-25.

引用本文的文献

1
Achieving reproducibility in the innovation process.在创新过程中实现可重复性。
Open Res Eur. 2025 Jun 30;5:25. doi: 10.12688/openreseurope.19408.2. eCollection 2025.
2
Reporting of measures against bias in nonclinical published research studies: a journal-based comparison.非临床已发表研究中针对偏倚的测量报告：基于期刊的比较
Res Integr Peer Rev. 2025 Aug 29;10(1):17. doi: 10.1186/s41073-025-00176-w.
3
Condition-dependent effects of knockdown of autophagy on longevity.自噬敲低对寿命的条件依赖性影响。

本文引用的文献

1
Trial watch: Phase II failures: 2008-2010.试验观察：II期试验失败情况：2008 - 2010年
Nat Rev Drug Discov. 2011 May;10(5):328-9. doi: 10.1038/nrd3439.
2
Factors affecting reproducibility between genome-scale siRNA-based screens.影响基于全基因组规模小干扰RNA筛选的重复性的因素。
J Biomol Screen. 2010 Aug;15(7):735-47. doi: 10.1177/1087057110374994. Epub 2010 Jul 12.
3
What errors do peer reviewers detect, and does training improve their ability to detect them?同行评审人员能发现哪些错误，培训是否能提高他们发现错误的能力？
bioRxiv. 2025 Jul 31:2025.07.28.667102. doi: 10.1101/2025.07.28.667102.
4
Can I trust this paper?我能信任这篇论文吗？
Psychon Bull Rev. 2025 Jul 16. doi: 10.3758/s13423-025-02740-3.
5
GhostBuster: A Deep-Learning-based, Literature-Unbiased Gene Prioritization Tool for Gene Annotation Prediction.幽灵克星：一种基于深度学习、不受文献偏差影响的用于基因注释预测的基因优先级排序工具。
bioRxiv. 2025 Jun 27:2025.06.22.660948. doi: 10.1101/2025.06.22.660948.
6
Testing the usefulness of a quality system in preclinical research.测试质量体系在临床前研究中的实用性。
Neurosci Appl. 2024 Nov 13;4:105395. doi: 10.1016/j.nsa.2024.105395. eCollection 2025.
7
qByte: An open-source isothermal fluorimeter for democratizing analysis of nucleic acids, proteins and cells.qByte：一款用于普及核酸、蛋白质和细胞分析的开源等温荧光计。
PLoS Biol. 2025 May 28;23(5):e3003199. doi: 10.1371/journal.pbio.3003199. eCollection 2025 May.
8
Optimizing resazurin-based viability assays for P-MSC/TER308 cell line to enhance results reliability.优化基于刃天青的P-MSC/TER308细胞系活力测定方法以提高结果可靠性。
BMC Res Notes. 2025 May 22;18(1):228. doi: 10.1186/s13104-025-07298-w.
9
Quantification of glucagon and oxyntomodulin by protein precipitation-immunoaffinity enrichment-LC-MS/MS.通过蛋白质沉淀-免疫亲和富集-LC-MS/MS对胰高血糖素和胃泌酸调节素进行定量分析。
J Mass Spectrom Adv Clin Lab. 2025 Apr 11;36:37-45. doi: 10.1016/j.jmsacl.2025.04.002. eCollection 2025 Apr.
10
Replicability of bulk RNA-Seq differential expression and enrichment analysis results for small cohort sizes.小样本量时批量RNA测序差异表达及富集分析结果的可重复性
PLoS Comput Biol. 2025 May 5;21(5):e1011630. doi: 10.1371/journal.pcbi.1011630. eCollection 2025 May.
J R Soc Med. 2008 Oct;101(10):507-14. doi: 10.1258/jrsm.2008.080062.
4
Fate of submitted manuscripts rejected from the American Journal of Neuroradiology: outcomes and commentary.提交至《美国神经放射学杂志》后被拒稿件的命运：结果与评论
AJNR Am J Neuroradiol. 2007 Sep;28(8):1430-4. doi: 10.3174/ajnr.A0766.
5
Why most published research findings are false.为何大多数已发表的研究结果是错误的。
PLoS Med. 2005 Aug;2(8):e124. doi: 10.1371/journal.pmed.0020124. Epub 2005 Aug 30.
6
What happens to the manuscripts that have not been accepted for publication in Occupational and Environmental Medicine?那些未被《职业与环境医学》接受发表的手稿会怎样？
Occup Environ Med. 2001 Sep;58(9):604-7. doi: 10.1136/oem.58.9.604.